Mutations of the dimerization site of glycoprotein (GP) VI result in abolished expression

Glycoprotein (GP) VI is a transmembrane receptor of ~65  kDa only expressed on the megakaryocyte-platelet lineage [1]. GPVI, the central platelet collagen receptor that also binds fibrin and additional ligands, has emerged as promising anti-thrombotic target since it has only a limited role in hemostasis, but significantly contributes to thrombosis and ischemic stroke [2,3]. Recently, the positive results obtained by the humanized anti-GPVI Fab fragment Glenzocimab in a phase 1b/2a trial involving patients affected by acute ischemic stroke [4] underscore that targeting GPVI is a valid strategy to also treat thrombo-inflammatory diseases [5].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research